Category: AstraZeneca
-
Federal Circuit upholds decision to throw out $107.5M patent infringement verdict against AstraZeneca
The precedential decision, confirming the invalidation of two of Pfizer subsidiary Wyeth’s cancer drug-related patents, held that the plaintiff not only failed to rebut evidence on certain issues, but its own experts agreed against it.
-
Federal Circuit tosses Pfizer’s $42M+8% verdict against Daiichi, AstraZeneca: claiming 81 combinations out of gazillions described defeats disclosure, enablement
In a precedential opinion, the central U.S. appeals court for patent rulings overturns a Texas jury verdict given the discrepancy between a broad description and a specific claim term.
-
AstraZeneca faces fresh mRNA patent infringement allegations in District of Delaware
Gene-editing tech company Factor Bioscience has sued AstraZeneca and its affiliate Cellectis over the infringement of three mRNA-related patents.
-
Post-judgment cleanup orders in UK pharma cases: no disgorgement of Bayer profits; Teva, Glenmark, Generics (UK) recover two thirds of costs
AstraZeneca must reimburse two thirds of the costs of an unsuccessful case Teva, Glenmark and Generics (UK). Separately, Bayer does not have to disgorge profits to Sandoz.